Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CHIVA2
- 01 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2019.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.
- 10 Oct 2017 New trial record